Jie Zhang
Director of Chemsitry, Protagonist Therapeutics
PN-881: First-in-Class Oral Peptide Targeting the IL-17 Pathway
Abstract
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. In this showcase, we report one of the pre-clinical assets - PN-881: First-in-Class Oral Peptide targeting the IL-17 pathway, including its pre-clinical potency, metabolic stability, pharmacodynamic and efficacy results. Anticipate Phase 1 to be initiated in the fourth quarter of 2025.
Bio
Jie Zhang is a Director of Chemistry at Protagonist Therapeutics in Brisbane Australia. She has an extensive experience in peptides drug discovery and preclinical development, from peptides design, synthesis, structure-activity relationships to bio-analysis and DMPK optimization. She has been with Protagonist for over 15 years with increasing responsibility and has been a key member of the discovery team for many projects, including two Phase 3 candidates Icotrokinra and Rusfertide, and most recently IL-17 blocker PN-881. She received her Ph.D. in Chemistry from the University of Newcastle.